Jump Financial LLC Takes Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Jump Financial LLC purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 14,794 shares of the medical research company's stock, valued at approximately $2,731,000.

A number of other large investors have also recently modified their holdings of CRL. M&T Bank Corp boosted its position in shares of Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after acquiring an additional 66 shares during the last quarter. Virtu Financial LLC bought a new stake in Charles River Laboratories International in the 3rd quarter worth approximately $601,000. Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the 3rd quarter worth approximately $59,000. Tidal Investments LLC lifted its position in Charles River Laboratories International by 37.8% in the 3rd quarter. Tidal Investments LLC now owns 8,452 shares of the medical research company's stock worth $1,665,000 after buying an additional 2,319 shares during the last quarter. Finally, Lord Abbett & CO. LLC lifted its position in Charles River Laboratories International by 5.8% in the 3rd quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company's stock worth $21,413,000 after buying an additional 5,959 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Up 2.4 %

Shares of Charles River Laboratories International stock traded up $2.59 on Wednesday, hitting $109.48. 378,380 shares of the company traded hands, compared to its average volume of 1,493,073. The stock's 50 day moving average price is $149.12 and its 200-day moving average price is $172.68. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $254.15. The company has a market cap of $5.38 billion, a PE ratio of 729.87, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.46 earnings per share. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on CRL shares. Barclays decreased their price target on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Mizuho decreased their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Robert W. Baird decreased their price target on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Finally, William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $182.00.

Insider Activity

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James C. Foster acquired 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).